| 111.85 -2.77 (-2.42%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 139.25 |
1-year : | 144.83 |
| Resists | First : | 119.22 |
Second : | 124 |
| Pivot price | 117.93 |
|||
| Supports | First : | 111.5 |
Second : | 92.76 |
| MAs | MA(5) : | 113.8 |
MA(20) : | 118.43 |
| MA(100) : | 112.25  |
MA(250) : | 93.78 |
|
| MACD | MACD : | -1.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.7 |
D(3) : | 13.4 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 124.21 | Low : | 70.74 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MRK ] has closed above bottom band by 7.5%. Bollinger Bands are 32.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 114.15 - 114.81 | 114.81 - 115.4 |
| Low: | 110 - 110.71 | 110.71 - 111.35 |
| Close: | 110.83 - 111.97 | 111.97 - 112.99 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Sun, 26 Apr 2026
Merck KGaA: Small Breakout In 2026, Followed By Normalization (OTCMKTS:MKGAF) - Seeking Alpha
Fri, 24 Apr 2026
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO - Fierce Pharma
Wed, 22 Apr 2026
Exclusive: Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
Wed, 22 Apr 2026
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation - PR Newswire
Tue, 21 Apr 2026
US FDA approves Merck's pill combo to treat HIV infection - Reuters
Tue, 21 Apr 2026
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) - Merck.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,470 (M) |
| Shares Float | 2,470 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 81.3 (%) |
| Shares Short | 27,720 (K) |
| Shares Short P.Month | 31,120 (K) |
| EPS | 7.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.26 |
| Profit Margin | 28 % |
| Operating Margin | 32.7 % |
| Return on Assets (ttm) | 12 % |
| Return on Equity (ttm) | 36.8 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 20.32 |
| Sales Per Share | 26.31 |
| EBITDA (p.s.) | 11.78 |
| Qtrly Earnings Growth | -19.3 % |
| Operating Cash Flow | 16,470 (M) |
| Levered Free Cash Flow | 11,890 (M) |
| PE Ratio | 15.36 |
| PEG Ratio | 3.6 |
| Price to Book value | 5.26 |
| Price to Sales | 4.24 |
| Price to Cash Flow | 16.77 |
| Dividend | 0.85 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|